细胞外基质金属蛋白酶诱导因子在喉鳞状细胞癌组织中的表达  

Expression of extracellular matrix metalloproteinase in ducerin laryngeal squamous cell carcinoma

作　　者：马俭[1] 乔宗海[2] 吴四海[2] 

机构地区：[1]南京医科大学附属南京第一医院耳鼻咽喉科,南京210006 [2]南京医科大学第一附属医院耳鼻咽喉科

出　　处：《临床耳鼻咽喉科杂志》2005年第12期545-547,共3页Journal of Clinical Otorhinolaryngology

摘　　要：目的:了解细胞外基质金属蛋白酶诱导因子(EMMPRIN)在喉鳞状细胞癌(LSCC)及喉癌前病变的表达情况,探讨其与LSCC浸润和转移的关系。方法:用免疫组织化学SP法对42例LSCC、28例喉癌前病变和20例正常喉组织中的EMMPRIN表达情况进行检测。结果:EMMPRIN在LSCC和喉癌前病变的阳性表达率分别为88.1%和57.1%,明显高于正常喉组织的5.0%,Ⅲ～Ⅳ期LSCC组织的强阳性表达率为76.0%,高于Ⅰ～Ⅱ期的强阳性表达率17.6%。伴有颈淋巴结转移的LSCC组织的EMMPRIN强阳性表达率高于无淋巴结转移组。结论:EMMPRIN在LSCC有较高的阳性表达。EMMPRIN的表达与LSCC的分期和是否存在淋巴结转移有关。LSCC组织EMMPRIN的表达影响LSCC的浸润和转移。Objective:To study the expression of extracellular matrix metalloproteinase inducer(EMMPRIN/CD147) in human laryngeal squamous cell carcinoma and the relationship between the expressions and the clinical features.Method:The expressions of EMMPRIN were detected by the method of immunohistochemical SP in 42 specimens taken from the patients with laryngeal squamous cell carcinoma, 28 specimens from precancerous lension and 20 specimens from normal laryngeal tissues.Result:Positive expressions rates of EMMPRIN in the specimens from laryngeal squamous cell carcinoma, precancerous lension and normal laryngeal tissues were 88.1%, 57.1% and 5.0%, the intensive expressions rates were 52.4%, 10.7% and 0%. There were significant differences among laryngeal squamous cell carcinoma,precancerous lension and normal laryngeal tissues. In laryngeal squamous cell carcinoma, the expressions of EMMPRIN had a significant relevance to clinical phases and lymph node matastasis. The intense expsessions rate in phase Ⅲ-Ⅳ was much higher than that in phase Ⅰ-Ⅱ, while the intense expressions rate in cases with lymph node matastasis was higher than in those cases without lymph node matastasis.Conclusion:The expression of EMMPRIN has relationship with the pathological type of laryngeal tumor and has relevance to clinical stage and lymph node matastasis of laryngeal carcinoma.

关 键 词：喉肿瘤 癌 鳞状细胞 基质金属蛋白酶诱导因子 

分 类 号：R739.65[医药卫生—肿瘤]